Biomérieux third-quarter organic sales growth beats expectations (updated)
UPDATE 2-Biomérieux third-quarter organic sales growth beats expectations Adds broker's comment in bullet 4, share move in bullet 6
Nov 3 (Reuters) - French biotechnology firm Biomérieux BIOX.PA reported on Tuesday a better-than-expected organic sales growth in the third quarter, helped by a 13% increase across key growth areas under its GO28 strategic plan.
Total sales for the period came in at €1,042 million ($1.17 billion), up 8% year on year, above the company's compiled median consensus for sales of €1,007 million and organic growth of 5.9%.
Year-on-year growth at Clinical Applications, which make up 84% of total sales, reached 8% in the quarter, while Industrial Applications, 16% of sales, grew by 9%
BIOFIRE Non-Respiratory panels sales increased by 25% driven by "strong momentum across the entire portfolio", with the cyclosporiasis outbreak in the US boosting demand for BIOFIRE gastrointestinal panel
Biomérieux confirmed its guidance for the full year but added that it now expects a negative currency effect of about €35 million versus the earlier forecast of negative €40-50 million
The report offers reassurance regarding 2026, broker TP ICAP Midcap said in a note, but added that the debate on 2027–2028 is not settled
The company, which targets organic sales growth of 3%-6% per year in 2027 and 2028, aims to expand into women’s health with a new vaginitis panel set to enter the US market in early 2027
Biomérieux shares rose 5.5% at 0812 GMT to the top of France's broader SBF 120 .SBF120 index
($1 = 0.8937 euros)
(Reporting by Margaux Perrin in Gdansk, editing by Izabela Niemiec)
((Margaux.Perrin@thomsonreuters.com))
Recent news on Biomerieux SA
See all newsBrief: Biomerieux Receives US FDA 510(K) Clearance And Ivdr CE Marking For Vitek Pro
Brief: bioMerieux Receives FDA Clearance For Latest Versions Of Biofire® Filmarray
Europe Research Roundup: Asos, Erste Group, SCHOTT pharma
Europe Research Roundup: Acceler8 Ventures, Hermes, Soitec
BioMerieux shares rise after Q3 sales beat